Navigation Links
Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
Date:12/9/2008

ide in clinical studies for the treatment of heart failure; 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties; and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section in Item 1 of the Form 10-KSB we filed with the Securities and Exchange Commission on March 27, 2008. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
2. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
3. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
4. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
5. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
8. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
9. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
10. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
11. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues, today ... results will be released on Thursday, August 7, 2014, ... and live webcast at 4:30 p.m. ET that afternoon. ...
(Date:7/31/2014)... July 31, 2014 Boston’s Adult Stem ... flush with innovative adult stem cell biotechnologies. Currently ... and has three additional patent applications currently under examination ... patented inventions address two of the most vexing problems ... Adult stem cells are difficult to identify; and ...
(Date:7/30/2014)... and PARIS , July 30, 2014 ... SAN and NYSE: SNY) today announced that the Companies ... (FDA) rare pediatric disease priority review voucher in connection ...  The priority review voucher entitles the holder to designate ... expedited 6-month review from the filing date instead of ...
(Date:7/30/2014)... FRANCISCO , July 30, 2014 ... Congress evaluated the safety and efficacy of CSL ... rejection following kidney transplants in highly sensitized patients. ... inhibitor of the complement system. The ... in significant increases in the levels of complement ...
Breaking Biology Technology:BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... & Burling represented AstraZeneca in its $1.26 billion ... will pay $32 per share for all of ... (Logo: http://photos.prnewswire.com/prnh/20120423/CL92331LOGO  ) AstraZeneca ... primary focus on the discovery, development and commercialization ...
...  Melanie Pita, J.D., will offer her expert perspective ... hospitals as she presents "EHRs: Meaningful Use & ... Conference, being held  April 24-26, 2012, at the ... During the presentation, Pita, who serves ...
... Inc., a leading innovator of new life science tools, today ... of its innovative portable PCR system. The F1-12 system is ... high speed and sensitivity in a fully portable format. ... Standard Fast" speed levels delivering 30-cycle PCR amplification within ...
Cached Biology Technology:Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences 2Prognosis HIS Executive Slated To Offer EHR Advice At Illinois Rural Health Association Conference 2Ahram Biosystems Announces Launch of the New Economy Model F1-12 of Its Palm PCR Series 2
(Date:7/30/2014)... David L. Kaplan, Ph.D., will head the brand-new, web-only ... editor-in-chief. With the first issue slated for publication in ... in the rapidly burgeoning field of biomaterials, the study ... living or biological systems. , "This new journal is ... field of biomaterials over the past decade and the ...
(Date:7/30/2014)... distance between two points is a straight line, and ... taking the familiar axiom to heart. , Though ... intense, with each racing for the chance to fertilize ... form cooperative groups that allow them to take a ... study, conducted by Heidi Fisher, a post-doctoral student working ...
(Date:7/30/2014)... the University of Helsinki and the Universitat Autnoma de ... morphological changes which have taken millions of years to ... development of mice teeth, induced in the laboratory, scientists ... those observed in the fossil registry of rodent species ... , To modify the development of their teeth, the ...
Breaking Biology News(10 mins):ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2When cooperation counts 2When cooperation counts 3Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2
... This news release is available in German . ... bees are dying and insect diversity is dwindling. Only recently, both ... decline, which jeopardises food security. The (lack of) pollination has thus ... habitats, and organic farming. ETH-Zurich researchers from the group headed ...
... CAMBRIDGE, Mass. , June 5, 2013  Emotient, the ... leading eye tracking and biometric software platform company, today ... and Yale University are the first customers of a ... analysis, eye tracking, EEG and GSR technologies. The combined ...
... new study finds that utilities aren,t rewarded for adopting ... make energy efficiency as attractive as renewables. The ... Environmental Law , examines key differences between energy efficiency ... professor at Oregon State University, outlines ways to increase ...
Cached Biology News:Pollination merely 1 production factor 2Pollination merely 1 production factor 3Pollination merely 1 production factor 4Emotient and iMotions Partner to Offer Unique Integrated Facial Expression Recognition, Bio Sensor and Eye Tracking Solution for Usability, Gaming, Market and Academic/ Scientific Research 2Emotient and iMotions Partner to Offer Unique Integrated Facial Expression Recognition, Bio Sensor and Eye Tracking Solution for Usability, Gaming, Market and Academic/ Scientific Research 3Emotient and iMotions Partner to Offer Unique Integrated Facial Expression Recognition, Bio Sensor and Eye Tracking Solution for Usability, Gaming, Market and Academic/ Scientific Research 4Study finds disincentives to energy efficiency can be fixed 2
... Gasket slide kit (1x 22K gasket/slide) G2534-60003 ... or Gasket slide kit (2x 11K ... slides offered in either 11K or 22K microarray feature ... gaskets are carefully fabricated and batch tested to ensure ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... locking design in ice/water bath This ... number, created to easily match Cornings ... yet, please order under the old ... service for assistance. ID clarifier: rack ...
... Microarray Kit (V2), 2 x 11K ... expression of many thousands of yeast ... important biological processes. Each microarray contains ... ORFs from the S288C strain of ...
Biology Products: